Venetoclax is an oral, small-molecule BCL-2 inhibitor that was approved for the treatment of relapsed/refractory (R/R) CLL (including small lymphocytic lymphoma [SLL]) in combination with rituximab in Japan in September 2019 [4, 5]. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.